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Insights into ALS pathomechanisms: from flies to humans
Andrea Chai1,2 and Giuseppa Pennetta1,2,*
1Euan McDonald Center for Motor Neurone Disease Research; 2Centre for Integrative Physiology; University of Edinburgh; Edinburgh; UK
Amyotrophic Lateral Sclerosis (ALS)is a devastating neurodegenerative
disease causing the death of motor neu-
rons with consequent muscle atrophy
and paralysis. Several neurodegenerative
diseases have been modeled in Drosophila
and genetic studies on this model organ-
ism led to the elucidation of crucial
aspects of disease mechanisms. ALS,
however, has lagged somewhat behind
possibly because of the lack of a suitable
genetic model. We were the first to
develop a fly model for ALS and over the
last few years, we have implemented and
used this model for a large scale, unbiased
modifier screen. We also report an exten-
sive bioinformatic analysis of the genetic
modifiers and we show that most of
them are associated in a network of inter-
acting genes controlling known as well as
novel cellular processes involved in ALS
pathogenesis. A similar analysis for the
human homologues of the Drosophila
modifiers and the validation of a subset
of them in human tissues confirm and
expand the significance of the data for
the human disease. Finally, we analyze a
possible application of the model in the
process of therapeutic discovery in ALS
and we discuss the importance of novel
“non-obvious” models for the disease.
Introduction
Amyotrophic Lateral Sclerosis (ALS) is
a fairly common neurodegenerative dis-
ease characterized by the selective death of
motor neurons and a progressive decline
in muscle function leading to paralysis,
speech deficits and eventually death due to
respiratory failure.1 ALS was first
described more than 130 years ago by the
French neurologist Jean-Martin Charcot
and yet, the understanding of the molecu-
lar mechanism underlying disease patho-
genesis remains elusive.2,3 The disease
usually appears in midlife and causes
death within 3 to 5 years after clinical
onset.1
Approximately 10% of ALS cases are
inherited and are classified as familial
while the majority are sporadic with no
apparent genetic cause. Familial and spo-
radic ALS cases share common pathologi-
cal features leading to the hypothesis that
studying the mechanism of disease patho-
genesis for the familial cases will provide
relevant information for the more com-
mon sporadic cases.1
In 1993, missense mutations in the gene
encoding the Cu/Zn superoxide dismutase
1 (SOD1) in a subset of ALS familial
cases,4 led to the conviction that finding a
therapy for this devastating disease was
going to be a relatively simple task. Since
the normal function of SOD1 is the con-
version of superoxide anions into hydrogen
peroxide, it was initially thought that a
decrease in its catalytic activity with a con-
sequent accumulation of free radicals is
responsible for the toxic effect associated
with ALS-causing SOD1 alleles. However,
subsequent studies focusing on the elucida-
tion of the mechanism underlying SOD1-
mediated toxicity revealed that understand-
ing this mechanism was unexpectedly chal-
lenging. Several lines of transgenic mice
expressing various ALS-causing SOD1 var-
iants were generated and they were found
to recapitulate major hallmarks of the
human disease.5 However, studies on these
murine models showed that various SOD1
mutations exhibit a remarkably high degree
of variability in their enzymatic activity and
more importantly, there is no direct
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correlation between the degree of this activ-
ity on one hand and the onset and severity
of the disease on the other hand.5 These
data together with the finding that SOD1
knock-out mice do not develop motor neu-
rone diseases led to the conclusion that
ALS-causing SOD1 variants are not loss-
of-function alleles but rather neo-morphs
that have acquired new toxic properties.5
Initial attempts to generate Drosophila
models for SOD1-induced ALS, provided
disappointing results as well.6 Expression
of Drosophila Sod gene in a number of tis-
sues has little or no effect on life-span
while expression of its human homolog in
flies increases life-span more than 40%.7
In contrast to mice knockout for SOD1,
flies deficient for the same gene exhibit
early lethality that can be rescued by the
targeted expression of the SOD1 human
gene in motor neurons.8 Additionally,
high levels of expression of ALS causing
SOD1 alleles in Drosophila motor neurons
have no deleterious effects but instead
induce a significant extension in fly life-
span and rescue the mutant phenotype
due to the inactivation of the fly endoge-
nous gene.9 Hence, the toxic effect associ-
ated with the expression of ALS causing
SOD1 alleles in mice and in humans is
not observed in Drosophila.
A more recent study showed that
motor neuron specific expression of wild-
type or disease-linked mutants of human
SOD1 in Drosophila does not affect life-
span but instead induces a progressive
decline in locomotion activity that is asso-
ciated with defective neuronal physiology
and induction of stress response in sur-
rounding glia cells. However, these phe-
notypes were not accompanied by a
decrease in neuronal viability despite the
fact that neurons exhibit a severe accumu-
lation of mutant SOD1-induced aggre-
gates.10 Recently, another paper has been
published reporting that transgenic flies
expressing a Zn-deficient SOD1 allele dis-
play a progressive decline in locomotion
performance and in their muscles accumu-
lation of abnormal mitochondria and
reduced ATP production are observed.
However, these flies do not exhibit any
neuronal degeneration and their life-span
is normal.11
In conclusion, many transgenic SOD1
mice mimicking the human disease are
available and several attempts have been
made to generate a fly model for this type
of ALS, nevertheless, the mechanism of
SOD1-mediated toxicity remains an open
question.
In 2004 more than 10 y after the iden-
tification of SOD1 as an ALS causative
gene, a missense mutation in a conserved
region of the human VAMP/Associated
Protein B (hVAPB) was shown to cause a
range of motor neuron diseases including
spinal muscular atrophy, atypical ALS and
typical ALS (ALS8).12 The ALS causative
mutation replaces the Proline in position
56 with a Serine (P56S) and this amino
acid residue is conserved from yeast to
man. We and other labs generated a first
Drosophila model for ALS8 by expressing
the Drosophila protein carrying the ALS8
causing mutation (DVAP-P58S) in flies.
Expression of the disease transgene in neu-
rons recapitulates major features of the
human disease including aggregate forma-
tion, neurodegeneration, locomotion
defects and decreased life-span.13-16
Recently, 2 additional missense mutations
in hVAPB have been shown to cause
ALS8 in humans. Expression of these
mutant transgenes in flies also reproduces
hallmarks of the human disease confirm-
ing that Drosophila is an excellent system
in which to model ALS8.17,18
Loss of DVAP function results in struc-
tural changes at the larval neuromuscular
junction (NMJ) that are characterized by
a decrease in the number of synaptic bou-
tons and an increase in their size while
presynaptic overexpression of the same
protein leads to an increase in the number
of boutons and a decrease in their size.19
These morphological changes are accom-
panied by an increase in the number of
active zones in the DVAP mutants and a
decrease of vesicle density in DVAP over-
expressing synapses. Despite the observed
structural remodelling at the larval NMJ,
the synaptic response following nerve
stimulation remains the same in both gen-
otypes and is similar to the wild-type.
However, quantal size was found to be
increased in DVAP mutants and decreased
in DVAP overexpressing synapses suggest-
ing that compensatory changes in quantal
size may be responsible for maintaining
synaptic response within functional
boundaries. In agreement with these
changes in synaptic physiology, DVAP
expression levels affect the abundance of
specific subunits of postsynaptic glutamate
receptors and the volume of the postsyn-
aptic receptor clusters.13
Interestingly, similar alterations in syn-
aptic morphology are associated with the
expression of the human protein hVAPB
in fly neurons and more importantly,
expression of hVAPB in a mutant back-
ground for DVAP rescues the synaptic
phenotypes and the lethality associated
with DVAP mutants.13 Taken together,
these data clearly show that the human
and Drosophila proteins are functionally
interchangeable and that information
gained by studying the function of DVAP
can be relevant to the function of its
human homolog. Moreover, the N-termi-
nal fragment of VAP proteins encoding
the major sperm protein (MSP) domain,
has been shown to be secreted and to con-
trol mitochondria structure and function
in muscles by interacting with a number
of axon guidance receptors such as Ephrin
receptors, Robo and Lar-like protein tyro-
sine phosphatases.14,20
Interacting DVAP proteins have been
recently identified and they include the
oxysterol binding proteins and the Down
syndrome cell adhesion molecule
Dscam.21,22 DVAP protein interacts with
the cell-adhesion molecule Dscam and
determines its localization at the axonal
processes where Dscam affects axonal
branching by controlling self-recognition
and avoidance processes between neu-
rons.22 Finally, DVAP has been shown to
co-localize with the phosphoinositide
phosphatase Sac1 (Suppressor of Actin 1)
to control phosphoinositide levels in neu-
rons. Moreover, expression of the ALS8
allele in neurons sequesters Sac1 into the
aggregates leading to its inactivation. The
consequent increase in phosphoinositide
levels induces structural changes at the
NMJ and neurodegeneration. Notably,
inactivation of the corresponding phos-
phoinositide kinase in neurons decreases
phosphoinositide levels and suppresses
DVAP-P58S neurodegenerative phenotype
in the eye. Taken together, these data show
that increase in phospoinositide levels plays
a crucial role in ALS pathogenesis and
identify phosphoinositide kinases as a pos-
sible target for therapeutic intervention.16





































Over the past 5 years, a number of addi-
tional genes have been shown to cause ALS
and the vast majority of them can be clustered
into 2 functional categories: genes affecting
RNA metabolism such as TDP43 and FUS
and genes that affect protein degradation by
controlling the 2 major protein clearance
pathways: the autophagy and the ubiquitin/
proteasome system.23 VAP proteins have
been shown to participate in protein clearance
by controlling the unfolded protein response
that appears to be defective when the ALS8-
linked mutation is expressed.17,24 Studies in
Drosophila and mammalian cells showed that
P56S disease variant is a loss of function allele
by a dominant negative mechanism as it inac-
tivates the wild-type activity by sequestering
the endogenous protein into the cytoplasmic
aggregates.15,16,25 In line with the proposed
disease mechanism, hVAPB levels have been
found to be decreased in all sporadic cases
investigated26 and in ALS mouse models for
TDP-43 and SOD1.27,28 Moreover, TDP-
43 associates with VAPB-positive aggregates
in transgenic mice expressing the P56S dis-
ease-linked allele and the ALS causative gene
FUS binds hVAPB RNA.29,30 Collectively,
these data indicate that hVAPB plays an
important role in ALS pathogenesis; however,
the molecular mechanism underlying ALS8
pathogenesis remains poorly understood.
Here we show how systematic and
unbiased survey of the Drosophila genome
to search for genetic modifiers of the
ALS8 phenotypes can lead to the discov-
ery of important and possibly, novel genes
involved in disease pathogenesis. We also
show that by combining Drosophila genet-
ics and computational approaches of net-
work analyses with subsequent validation
of selected modifiers in human tissues,
fundamental and conserved pathways
underlying ALS pathogenesis can be
revealed and elucidated. Finally, we dis-
cuss how the use of a Drosophila model
can assist in the identification of pharma-
cological targets for therapeutic interven-
tion and the importance of searching for
novel and non-obvious models of diseases.
Generation of the ALS8 Fly Model
and Screening Strategy
One way to identify missing compo-
nents within a genetic network is to
conduct a screen for enhancers and
suppressors of specific phenotypes.
Although it is true that any screen will
perhaps identify enough genes to keep a
laboratory busy for many years, per-
forming a screen and characterizing the
identified hits require an enormous
amount of work. Therefore, it is impor-
tant to spend some time in designing a
rapid and effective screening strategy. A
preliminary and key consideration is to
generate a Drosophila model and to
determine the most suitable phenotypic
readout for the modifier screen. The eye
is by far the most popular place in
which to conduct such screens because
it is easy to score, it is not essential for
viability and more importantly, it has
been shown to represent an excellent
phenotypic readout in successful modi-
fier screens using Drosophila models of
neurodegenerative diseases.31 Moreover,
it is in general quite difficult to deter-
mine a priori whether a screening strat-
egy is going to be successful or not and
therefore it is important to test the sen-
sitivity of the disease model in detecting
genetic modifiers by performing a quick
pilot screen. Bearing this in mind, we
found that expression of the UAS-
DVAP-P58S transgene in the eye by
using the eyeless-GAL4 driver induces a
robust eye phenotype characterized by
reduced size, fused ommatidia, missing
and occasionally, extra bristles.16 As a
tester line for the screen we selected a
transgenic DVAP-P58S line that displays
a reduction of the eye size to approxi-
mately 30% of the wild-type value
when flies containing one copy of the
transgene are raised at 30C. A similar
phenotype is associated with the expres-
sion of a double copy of the transgene
in flies raised at 25C while flies
expressing one copy of DVAP-P58S at
28C have a less severe phenotype.
Taken together, these data clearly show
that the reduction in eye size is not an
experimental artifact caused by the
increased temperature but is due the
expression of the DVAP-P58S transgene
and it is dependent on its dosage. Addi-
tionally, the decrease in eye size to
approximately 30% of the wild-type
value represents an excellent quantitative
metric of modifying effects.
For simplicity, in the screen we used as
a tester line flies expressing one copy of
the DVAP-P58S transgene raised at 30C.
We screened the DrosoDel collection of
deficiencies that includes 209 non overlap-
ping deletions of genomic regions32 and 9
deficiencies were found to suppress while
5 were found to enhance the eye pheno-
type (unpublished data, Fig. 1). This
approach showed that the tester line could
identify potential modifiers. However, it
turned out that at least for the deficiencies
that were tested, the identification of the
interacting genes using available P ele-
ment-induced mutations was quite diffi-
cult. This can be due to the fact that
hypomorphic mutations in genetically
redundant genes may not display any
modifying effect or that the modifying
effect of genomic deficiencies is due to the
simultaneous removal of 2 or more differ-
ent genes uncovered by the deficiency.33,34
Both scenarios may preclude, or at least
make the identification of the interacting
genes difficult. We therefore decided to
screen lines in which the affected gene is
overexpressed. Results from this screen
have been reported elsewhere.35 Here we
describe and critically discuss these data.
For rapid identification of the modifier
genes, we screened a total of 1,136 P-ele-
ment insertion lines mainly from the EP
and the EPgy2 collections. We selected
these lines among those that based on the
position and orientation of the P-element
insertion, were predicted to induce an
overexpression of a neighboring gene.
Additionally, we selected lines with the
potential to disrupt the function of the
affected genes (where the P-element was
inserted in the opposite direction) for 47
EP and EPgy2 lines that have no obvious
overexpressing lines. In short, a total of
1,183 lines were screened. 85 modifiers
comprising 71 suppressors and 14
enhancers were identified in this primary
screen. The 7% calculated hit rate is
slightly higher than the 1–4% typically
observed in similar screens, demonstrating
the success of the screen in identifying
modifiers. To exclude possible false posi-
tive, the modifying effect of these mutant
lines was validated by using an indepen-
dent allele and an additional assay.
Pan-neural expression of DVAP-P58S






































at 30C. However, about 70% of the off-
spring survive when these flies are raised
at 28C. Survivors exhibit a normal loco-
motion behavior upon eclosion but 4 d
later, they experience a progressive decline
in climbing ability and at day 10 they
exhibit severe incoordination and eventu-
ally, paralysis. Controls do not display any
alterations in motor performance over the
entire time period of the assay.
Interestingly, we found that the large
majority of modifiers affect both disease
phenotypes in the same direction and
overall, there was a strong correlation
between the degree of the modifying effect
on the neurodegeneration and on the
locomotion defects, suggesting that these
2 phenotypic readouts effectively converge




Although our screen covered
less than 10% of the Drosophila
genome, we identified a fairly high
number of modifiers by screening
collections of available mutant
lines. Over the past few years,
advances in bioinformatics have
provided researchers with power-
ful analysis tools that are of invalu-
able importance in interpreting
large sets of experimental data and
in expanding their significance.
A first step in this analysis is
the ability to organize the identi-
fied modifiers in functional cate-
gories and to determine those
functional categories that are
overrepresented within the set of
phenotype modifying genes.
Ranking the genetic modifiers
into a list of enriched functional
categories can help in under-
standing the relative importance
of specific cellular processes for
the disease pathogenesis while
the clustering of several modifiers
within the same category vali-
dates the process as being impor-
tant for the disease. Additionally,
accurate and extensive computa-
tional analysis of large data sets
of genetic data can inform and
guide further experimental inves-
tigations. Hence, we undertook
bioinformatic approaches and we
performed an extensive computa-
tional analysis of modifier genes
in order to extrapolate cellular
processes and to define the net-
work of interacting genes under-
lying ALS pathogenesis.
The 85 modifier genes were
analyzed using the R/Bioconduc-
tor package ‘topGO’36 and this analysis
revealed that a variety of cellular processes
may be involved in ALS pathogenesis.
Among them, topGO identified endoso-
mal regulation, lipid particles, vesicular
trafficking and cell proliferation/apoptosis
as the most enriched functional categories.
To further extend our analyses we
searched the GeneMania database to
determine whether the list of identified
Figure 1. Df(3L)ED225 suppresses DVAP-P58S-induced eye phenotype. Scanning electron microscopy
images of (A) ey-Gal4/C control flies, (B) ey-Gal4, UAS-DVAP-P58S/C and (C) ey-Gal4, UAS-DVAP-P58S/C;
Df (3L)ED225/C flies. Flies in (D), (E) and (F) are higher magnifications of the genotypes in (A), (B) and (C)
respectively. Scale bars: 100 mm. (G) 60% of ey-Gal4, UAS-DVAP-P58S/C flies (white) have eye size areas cen-
tered between 1500 and 2000 arbitrary square units (ND61, SDD654) and 5% had eye sizes around 50 arbi-
trary square units compared to 74% of ey-Gal4, UAS-DVAP-P58S/C; Df(3L)ED225/C flies (black) that are
centered between 3000 and 3500 arbitrary square units and 10% at 4000 arbitrary square units (ND36,
SDD378) that is toward control values (60% centered around 4500 arbitrary square units and 20% centered
around 4000 and 4750 arbitrary square units respectively. Grey, ND20, SDD261). Differences between eye
size distributions of ey-Gal4, UAS-DVAP-P58S/C flies and ey-Gal4, UAS-DVAP-P58S/C; Df(3L)ED225/Cflies were
highly significant (P<0.001, according to the non-parametric Mann-Whitney U test when comparing the 2
data sets). Differences between the distributions of eye sizes between ey-Gal4, UAS-DVAP-P58S/C and control
flies were highly significant (P<0.001, according to the non-parametric Mann-Whitney U test when compar-
ing the 2 data sets). (H). Table reporting that the deficiency screen identified 9 genomic deficiencies as sup-
pressors and 4 as an enhancers of the DVAP-P58S eye phenotype. Sem experiments were performed as
previously described.16 Quantification of the eye phenotype was performed using Oculus v.1, an in-house
developed software.17





































Drosophila modifiers can be connected
into an interactome based on physical and
genetic interactions as well as co-localiza-
tion studies.37 Out of the 85 genetic
modifiers identified, 72 were found to
interconnect as a complex interactome,
while previous studies have identified 7 of
the modifiers (CG7324, Syx7, Ero1L,
Rab5, CG5118, rho and Spp) as DVAP
binding partners. Collectively, these data
confirm and expand cellular processes and
molecular pathways associated with
DVAP functions and provide insights into
possible molecular mechanisms underly-
ing ALS8 pathogenesis in vivo.
Relevance of the Drosophila Data
for the Human Disease
Perhaps the main and ultimate reason
for undertaking genetic modifier screens
in Drosophila is the ability to identify the
human orthologues of the fly modifier
genes that may represent risk factors or be
causative of the human disease.
We used DIOPT, a recently developed
tool for ortholog mapping,38 and we
found that out of the 85 modifiers 77
have a human homolog. The human genes
were subjected to analysis with the DIST
tool on DIOPT (http://www.flyrnai.org/
diopt-dist) to determine whether any of
them is known to be associated with any
neurological disorder in humans. Infor-
mation retrieved from the Online Mende-
lian Inheritance in Man data sets and
Genome-Wide Association Studies indi-
cates that a considerable number of
human homologues of the fly modifiers is
associated with neurodegenerative diseases
such as Parkinson and Alzheimer diseases
as well as spinocerebellar ataxias and mul-
tiple sclerosis. Other human orthologues
were linked to psychiatric disorders such
as schizophrenia, mental retardation and
autism spectrum disorder. Although these
data need to await experimental valida-
tion, they indicate that molecular com-
monalities exist between ALS8 and a
broad range of neurological disorders.
As for the Drosophila genes, to deter-
mine whether the human orthologues of
the DVAP-P58S modifiers could be linked
into a molecular network of interacting
genes, we turned to the Ingenuity Pathway
Analysis (IPA database, Ingenuity system
at www.ingenuity.com) database that inte-
grates a variety of experimental sources
including proteomic studies to establish
relationships between human genes. The
resulting human interactome included
hVAPB and 31 additional genes out of
the 77 human homologues. More impor-
tantly, these genes are also components of
the Drosophila genetic network showing
that a significant overlap exists between
the fly and the human interactomes, con-
firming the relevance of the fly data for
the disease pathogenesis in humans. To
expand the network of the human inter-
acting genes, we searched the IPA database
for genes interacting with hVAPB and we
included these genes in the list of the 77
human orthologues. By doing this, we
were able to expand the network of
human interacting genes and include 12
additional human genes homologous to
the Drosophila modifiers that were not
inserted in the first interactome.
To analyze the in vivo relevance of the
computational data, we focused on a sub-
network of computationally predicted
interactors that includes Drosophila proteins
implicated in endocytosis and vesicular traf-
ficking based on GeneMania data base. A
similar network was generated for the
human orthologues of these genes using
the IPA database. One of the gene that is
part of both networks is Rab7, a marker
for late endosome that was not identified
by the screen, although upregulation of the
early endosome marker Rab5 was found to
be a potent suppressor of the disease phe-
notypes in flies. Interestingly, overexpres-
sion or constitutive expression of Rab7 was
also found to be a potent suppressor of
both the neurodegenerative and the loco-
motion defect phenotypes confirming the
in vivo relevance of computationally
derived interactions. Furthermore, Rab5
abnormally accumulates in the DVAP-posi-
tive inclusions in eye imaginal discs and
brains expressing the pathogenic transgene.
A similar redistribution of Rab5 was
observed in post-mortem spinal cord tissues
of ALS patients where Rab5 immuno-reac-
tivity was found to form clusters and to
partially co-localize with hVAPB aggre-
gates. Interestingly, we noticed that, in con-
trols, hVAPB immunoreactivity was
restricted to large motor neurons where it
appears as a granular staining diffused
throughout these large cells.
Among the computationally predicted
interactors there were also SOD1 and the
causative gene of Huntington’s disease
huntingtin. Further experiments need to
be performed to validate the in vivo rele-
vance of these novel and potentially inter-
esting interactions.
In summary, we show that computa-
tional analysis can help to understand but
also to expand the significance of large
data sets derived from genetic modifier
screens in Drosophila. A careful analysis of
computationally predicted interactomes
may also guide further experimental inves-
tigation (Fig. 2).
Repurposing the ALS8 Model
The DVAP-P58Smodifier screen led to
the identification of genes that were
known to function in the disease patho-
genesis or to be interacting partners of
VAP proteins. As an example, a strong
modifier was found to be the gene rdgBb,
a phosphoinositide phosphatase that has
not been extensively characterized so far
but is supposed to function in the same
way as its closely associated isoform rdgB.
RdgB is the homolog of Nir2 in humans
that has been reported to interact with
VAPB to control Golgi trafficking in
human cell lines.39 A significant number
of modifiers were genes involved in
autophagy and the ubiquitin/proteasome
system further supporting the role of pro-
tein clearance in ALS pathogenesis.
In an unbiased modifier screen however,
one would wish to identify novel and so far
unrecognized, processes as crucial contribu-
tors of disease pathogenesis. We were sur-
prised to find that a number of genes
controlling lipid droplet (LD) biogenesis
and dynamics function as potent suppres-
sors of the ALS8 disease phenotypes. LDs
are organelles devoted to the storage and
supply of neutral lipids. Although it is
becoming increasing clear that LDs play a
fundamental role in processes other than
fat storage and mobilization,40 we do not
know at the moment how alterations in
LD biology could affect neuronal function
and survival in ALS. However, previous






































DVAP is a protein associated with LDs41
and during starvation, abnormal clusters of
LDs are observed in striated muscles of
both C. elegans and mice in which the
DVAP homolog gene has been inacti-
vated.42 Among the identified modifiers,
there is a striking enrichment for genetic
pathways controlling cell proliferation and
apoptosis such as the Ras pathway and the
Hippo (Hpo) tumor suppressor pathway.
Remarkably, we reported that DVAP-
P58S-induced ALS phenotypes were sensi-
tive to the dosage of a number of genes
within the Ras pathway that function
upstream of Raf and downstream of Ras
including connector enhancer of KSR
(CNK), Src42 and 14–3–3z.
Interestingly, reducing the expression
levels of Hpo, a tumor suppressor gene,
using 2 independently generated alleles
suppresses both ALS8 phenotypes, the
neurodegeneration and locomotion
defects. This suggests that Hpo is likely
up-regulated in neurons expressing the
DVAP-P58S transgene. Multiple lines of
evidence converge to support the role of
Hpo in ALS8 pathogenesis. Firstly, Hpo
has been reported to promote apoptosis
by reducing the expression levels
of a number of downstream tar-
gets including Drosophila inhibi-
tor of apoptosis 1 (DIAP1).43
In fact, in DVAP-P58S mutant
background, DIAP1 is downregu-
lated while DVAP-P58S-induced
neurodegeneration is alleviated by
an up-regulation of DIAP1.16
Secondly, Hpo overexpression
represses cell proliferation and
induces apoptosis44 and crucially,
its mammalian homolog MST1
is hyperactivated in post-mortem
tissues of ALS patients while its
down-regulation attenuates dis-
ease symptoms in SOD1 mouse
models of ALS.45 Lastly, DVAP
was identified as a high-confi-
dence member of the Hpo inter-
actome in high throughput
protein-protein interaction analy-
ses searching for additional com-
ponents of the Hpo pathway.46
It is important to underline
that genetic screens can also lead
to the identification of potential
targets for therapeutic interven-
tion. This is indeed the case for
Hpo since compounds acting as
inhibitors of Hpo activity and
therefore with the potential to
suppress the ALS8 disease pheno-
types, are available.47
The contribution of this Dro-
sophila model to the discovery
process of therapeutics for ALS8
however, may go beyond the sim-
ple identification of a potential
therapeutic target as it can also be
used as a platform for low to
high throughput drug screening.
Traditional approaches in high through-
put drug screening of chemical com-
pounds rely on studies in cell culture
systems and on biochemical assay. Most
positive hits identified through these
types of in vitro assays turn out to be
ineffective or toxic in subsequent valida-
tion experiments using rodent animal
models.48 Ideally, one would like to per-
form primary drug screenings of large
collections of compounds directly in
whole animals but traditional murine
models cannot be used because of time
and highly prohibitive costs of the
Figure 2. Flowchart of the screen for genetic modifiers of ALS8. The screening process in Drosophila followed
by computational analysis of modifiers both in Drosophila and in humans and validation of a specific subset
of modifiers in human tissues are depicted.





































experiments. Drosophila is emerging as an
excellent platform for medium to high
throughout screenings of thousands of
molecules that can quickly identify a
number of high quality lead compounds.
This approach depends on fully or par-
tially automated scoring of visible pheno-
types including eye morphological
phenotypes, viability and simple behav-
ioral assays such as climbing activity. The
Drosophila ALS8 model we present here
exhibits all of the features that would be
required for such application.
While preparing this manuscript, 2
large-scale modifier screens for C9orf72-
related ALS using the eye neurodegenera-
tive phenotype as a phenotypic readout
led to the identification of nucleocytoplas-
mic transport as a crucial contributor of
ALS pathogenesis. Drosophila data were
confirmed in human mammalian cells
lines and in induced pluripotent stem cells
derived from ALS patients affected by a
C9orf72-linked ALS. These results
obtained using other Drosophila models
for ALS confirm and reinforce the role of
Drosophila in identifying and elucidating
fundamental aspects of ALS pathogenesis
relevant for the human disease.49,50 These
data also indicate that morphological
alterations in the adult eye due to the tar-
geted expression of disease causative genes,
represent for ALS as for other neurodegen-
erative diseases, a powerful phenotypic
readout in large scale screens for genetic
modifiers.
Despite these results, one could still
wonder how a smaller and rough eye phe-
notype in flies could be compared with
the pathological features of complex
human diseases such as ALS.
The recently emerged concept of
“phenologs” may revolutionize the way we
conceive a model of a human disease. It is
becoming increasingly clear that genes are
not conserved during evolution as inde-
pendent entities but rather as a set of
interacting genes that can be repurposed
to control divergent processes in different
species.51 Recent studies have shown that
divergent processes such as angiogenesis in
mutant mice and growth rate of yeast
exposed to the hypercholesterolemia drug
lovastatin share a large number of ortholo-
gous interacting genes so that yeast can be
used as a model for angiogenesis in
mammals.51 These two phenotypes are
said to be “phenologs” since they present a
significant overlap in the network of inter-
acting genes despite the difference at the
organismal level in phenotypic outcomes
between the 2 species. Other examples of
“phenologs” have been described and this
discovery has led to the possibility that
non-obvious models may be used to iden-
tify previously unrecognized genes impor-
tant for a specific human disease.
In summary, it appears that Drosoph-
ila models of human neurodegenerative
diseases can have a variety of applica-
tions. They can be used to dissect the
molecular mechanisms underlying dis-
ease pathogenesis that may also lead to
the identification of specific therapeutic
targets. Models can provide a valuable
platform for screening large libraries of
chemical compounds, if suitable pheno-
typic readouts are available. Large scale
and unbiased genetic screens for modi-
fiers of Drosophila disease phenotypes
combined with bioinformatic analysis of
the identified hits can inform scientists
about the fundamental aspects of dis-
ease pathogenesis in humans and guide
further experimental investigations
(Fig. 2). Finally, the experimental strat-
egy we describe here provides a pool of
candidate genes that could inform
Genome-Wide Association Studies in
humans leading to an effective increase
in the rate of discovery of new disease
causative genes.
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